DRG Market Assessment reports

The therapeutic portfolio includes the descriptive content of the company’s therapy area such as franchise profile, sales analysis, pipeline analysis, deal and key events.

The therapeutic portfolio includes the descriptive content of the company’s therapy area such as franchise profile, sales analysis, pipeline analysis, deal and key events.

The drug profile includes the sales and forecast for the time period 2019 – 2030 for the United States and Rest of the World (ROW). It also covers the forecast summary and assumptions in terms of…

The therapeutic portfolio includes the descriptive content of the company’s therapy area such as franchise profile, sales analysis, pipeline analysis, deal and key events.

The therapeutic portfolio includes the descriptive content of the company’s therapy area such as franchise profile, sales analysis, pipeline analysis, deal and key events.

The drug profile includes the sales and forecast for the time period 2019 – 2030 for the United States and Rest of the World (ROW). It also covers the forecast summary and assumptions in terms of…

The therapeutic portfolio includes the descriptive content of the company’s therapy area such as franchise profile, sales analysis, pipeline analysis, deal and key events.

The therapeutic portfolio includes the descriptive content of the company’s therapy area such as franchise profile, sales analysis, pipeline analysis, deal and key events.

The treatment landscape for coronavirus disease 2019 (COVID-19) continues to evolve rapidly. Despite the availability of vaccines in the markets under study, research is ongoing to lower viral…

Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…

More than 30 million people in the United States are afflicted with osteoarthritic (OA) pain; we expect an aging population and the increasing prevalence of obesity to drive further growth…

TNF-alpha inhibitors continue to be the preferred choice to treat psoriatic arthritis (PsA) following failure on conventional DMARDs. However, other biologics such as IL-17 inhibitors (e.g.,…